CA8073 In re Merck & Co. Inc.
In re Merck & Co. Inc. Vytorin/Zetia Securities Litigation c/o Epiq Systems, Inc. Settlement Website Merck's $688M Vytorin Settlement Wins Judge's Nod. Inc. Vytorin/Zetia Securities Litigation, case number -cv-02177, and In re. The drug maker agreed to pay $688 million to settle two lawsuits that. In their heyday, Zetia and Vytorin were heavily promoted by Merck and.
Merck's $688M Vytorin Settlement Wins Judge's
Drug makers Merck & Co. and Schering-Plough Corp. will pay $41.5 million to settle lawsuits concerning their cholesterol drugs Vytorin and Zetia. The lawsuits. Welcome to the information website for In re Merck & Co. Inc. Vytorin/Zetia. reached a settlement of the Action with Defendants for $215,000,000 in cash the. Million Settlement – Zetia and Vytorin. Seeger Weiss LLP announced today a $41.5 million settlement with Merck & Co. Inc. and.
Merck to pay $688 million to settle Enhance lawsuits -
Vytorin pairs Zetia with the active ingredient of Zocor. Zetia helps block absorption of “bad” LDL cholesterol in the intestines, and Zocor helps. The settlement, according to plaintiffs attorneys, is one of the top 25. and Schering-Plough fell, and so did prescriptions of Zetia and Vytorin.